Novo Nordisk and Anthropic partner on AI research

• Novo Nordisk and Anthropic announced a collaboration to use Claude AI models in research and software development.
• The partnership will focus on drug discovery, biological reasoning, and AI-supported engineering.
• The companies will use defined data governance and human oversight frameworks.

Novo Nordisk (NYSE:NVO) and Anthropic announced a collaboration to apply Anthropic’s Claude AI models, including Claude Science, across Novo Nordisk’s research and development and software engineering activities.

The partnership will focus on using artificial intelligence to address drug discovery challenges, support biological reasoning, accelerate medicine development, and improve AI-assisted software development.

The agreement includes frameworks for data governance and human oversight as Novo Nordisk evaluates the use of AI models in research and technology workflows.

Novo Nordisk develops medicines focused on areas including diabetes, obesity, and other chronic diseases, while investing in research and digital technologies.

Anthropic develops artificial intelligence models, including Claude, designed for applications such as analysis, reasoning, and software development.

The collaboration reflects broader pharmaceutical industry efforts to apply AI tools to research processes, including drug discovery and scientific analysis.